ArticleNature microbiology2019
Targeting Type IV pili as an antivirulence strategy against invasive meningococcal disease.
Article in Nature microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 75 citations in OpenAlex.
- Insight into the relationship between type IV pilus function and biofilm formation.Biochemical Society transactions · 2026Review
- The role of type IV pilus in the interaction ofInfection and immunity · 2026Article
- An in vitro human vessel model to studyeLife · 2025Article
- Two-component systems as potential therapeutic targets inAnnals of medicine · 2025Review
- Structure-activity relationship study of benserazide derivatives as PilB inhibitors.RSC advances · 2025Article
- Article
- PlzR regulates type IV pili assembly in Pseudomonas aeruginosa via PilZ binding.Nature communications · 2024Article
- Beyond Antibiotics: What the Future Holds.Antibiotics (Basel, Switzerland) · 2024Review
- Angiopoietin-like 4 protects against endothelial dysfunction during bacterial sepsis.Nature microbiology · 2024Article
- Membrane platform protein PulF of themBio · 2024Article
- Structure and Dynamics of Type 4a Pili and Type 2 Secretion System Endopili.Sub-cellular biochemistry · 2024Review
- Effect of anti-biofilm peptideFrontiers in cellular and infection microbiology · 2024Article
- Type IV Pilus-Mediated Inhibition ofMicrobiology spectrum · 2023Article
- Vertebrate and Invertebrate Animal and New In Vitro Models for StudyingPathogens (Basel, Switzerland) · 2023Review
- High throughput and targeted screens for prepilin peptidase inhibitors do not identify common inhibitors of eukaryotic gamma-secretase.Expert opinion on drug discovery · 2023Article
- Type IV Pili Are a Critical Virulence Factor in Clinical Isolates of Paenibacillus thiaminolyticus.mBio · 2022Article
- The Structures and Binding Modes of Small-Molecule Inhibitors ofAntibiotics (Basel, Switzerland) · 2022Review
- Treatment of Wound Infections in a Mouse Model Using ZnACS nano · 2022Article
- Characterization ofFrontiers in microbiology · 2022Article
- External Stresses Affect Gonococcal Type 4 Pilus Dynamics.Frontiers in microbiology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial virulence factors are attractive targets for the development of therapeutics. Type IV pili, which are associated with a remarkable array of properties including motility, the interaction between bacteria and attachment to biotic and abiotic surfaces, represent particularly appealing virulence factor targets. Type IV pili are present in numerous bacterial species and are critical for their pathogenesis. In this study, we report that trifluoperazine and related phenothiazines block functions associated with Type IV pili in different bacterial pathogens, by affecting piliation within minutes. Using Neisseria meningitidis as a paradigm of Gram-negative bacterial pathogens that require Type IV pili for pathogenesis, we show that piliation is sensitive to altered activity of the Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.